Bay­er and AskBio re­veal ear­ly safe­ty da­ta for Parkin­son's gene ther­a­py, plot PhII study

Bay­er and its sub­sidiary AskBio tout­ed ear­ly da­ta from a small, ear­ly tri­al eval­u­at­ing the safe­ty of its gene ther­a­py for Parkin­son’s dis­ease and an­nounced plans for a Phase II study Thurs­day morn­ing.

The Phase Ib tri­al hit its pri­ma­ry end­point, which was to show the safe­ty of a one-time de­liv­ery of the gene ther­a­py, dubbed AB-1005, in­to 11 pa­tients split be­tween two co­horts. Six pa­tients had mild stage Parkin­son’s, while five had mod­er­ate stage.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER